Craig Hadfield Takes the Helm as New CEO of Volpara Amid Growth Surge

Lunit's New Leadership Direction

Lunit, a trailblazer in AI-driven solutions focused on cancer diagnostics and therapies, has announced a significant transition in its leadership structure. Craig Hadfield, previously Volpara's Chief Customer and Financial Officer, will step up as the new CEO of Volpara Health Technologies, effective April 1, 2025. This leadership change signals Lunit's commitment to enhancing its subsidiary's strategic direction and innovation, particularly within the breast health domain.

With nearly a decade of experience at Volpara, Hadfield's leadership has been integral to the company's evolution from a fledgling startup to a foremost player in breast health solutions. Since joining Volpara in 2016, he has been pivotal in guiding the company through various stages of growth, overseeing financial operations, strategic acquisitions, and transitioning the business to a Software as a Service (SaaS) model. His tenure as CFO from 2017 to 2024 was marked by impressive achievements, including an annual recurring revenue rise to over $34 million and achieving cash flow break-even for the first time in 2023. Notably, Hadfield played a crucial role in Volpara's acquisition by Lunit in 2023, further solidifying his importance in the company's trajectory.

Brandon Suh, CEO of Lunit, expressed full confidence in Hadfield's leadership, stating that his deep understanding of Volpara's operations and proven track record make him ideally suited to lead the company into its pivotal next phase. Suh noted, “We look forward to Craig's continued success in advancing Volpara's mission toward enhancing breast health solutions globally.”

In his own words, Hadfield expressed honor in accepting the role, stating, “I am committed to furthering Volpara's mission of transforming breast health through groundbreaking AI-powered solutions.” Having contributed significantly to Volpara's journey for nearly ten years, he is enthusiastic about collaborating with the talented team, partners, and clients to enhance their impact on breast cancer detection and patient care.

Hadfield's Background

Before his time at Volpara, Hadfield garnered extensive experience working in various capacities across South Africa, New Zealand, the Bahamas, and the United States, honing his skills in finance and customer relations. He is a qualified Chartered Accountant and has previously held key positions at both Ernst & Young (EY) and Deloitte. His academic credentials include a Bachelor of Commerce in Accounting and Finance and an Accounting Higher Diploma from the University of Witwatersrand in Johannesburg, South Africa.

About Lunit and Volpara Health

Founded in 2013, Lunit is regarded as one of the leading companies utilizing AI in the medical field, dedicated to combating cancer through advanced medical image analytics and biomarker analyses. The company aims to ensure accurate diagnoses and optimal treatments for cancer patients worldwide. Lunit's FDA-approved INSIGHT suite for cancer screening currently serves over 4,800 medical institutions across more than 55 countries. Additionally, the company has gained recognition in leading medical journals, including the Journal of Clinical Oncology and The Lancet Digital Health, showcasing its commitment to advancing cancer care.

Volpara Health, on its part, specializes in leveraging AI-driven software to assist healthcare providers in understanding cancer risks better, facilitating personalized care decisions, and recommending necessary imaging and interventions. With its software deployed in over 3,500 facilities serving over 18 million patients globally, it stands at the forefront of breast health technology, streamlining operations and aiding in compliance and accreditation requirements.

Under Hadfield's guidance, both Lunit and Volpara are poised to further their respective missions in the healthcare landscape, aiming for innovations that enhance patient care and outcomes.

Conclusion

As Craig Hadfield transitions into the CEO role at Volpara, the healthcare industry will undoubtedly be watching closely. His extensive experience and previous successes paint a promising picture for the future of breast health solutions, reinforcing Lunit and Volpara's positions as leaders in the fight against cancer.